APA (7th ed.) Citation

LM, S., SM, T., G, F., V, B., RO, A., B, W., . . . A, B. (2024). Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: Results from the NeoSTAR trial. Annals of oncology : official journal of the European Society for Medical Oncology, 35(3), 293. https://doi.org/10.1016/j.annonc.2023.11.018

Chicago Style (17th ed.) Citation

LM, Spring, et al. "Response-guided Neoadjuvant Sacituzumab Govitecan for Localized Triple-negative Breast Cancer: Results from the NeoSTAR Trial." Annals of Oncology : Official Journal of the European Society for Medical Oncology 35, no. 3 (2024): 293. https://doi.org/10.1016/j.annonc.2023.11.018.

MLA (9th ed.) Citation

LM, Spring, et al. "Response-guided Neoadjuvant Sacituzumab Govitecan for Localized Triple-negative Breast Cancer: Results from the NeoSTAR Trial." Annals of Oncology : Official Journal of the European Society for Medical Oncology, vol. 35, no. 3, 2024, p. 293, https://doi.org/10.1016/j.annonc.2023.11.018.